RxDoctor Payments Data

Nicholas Willard, PA

Physician Assistant · Dothan, ALNPI 1861065740

Payments from drug & device makers

$5,843in general payments, 2019–2025

Across 162 payments — averaging $36.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Penumbra, Inc.$2K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$483
  • E.r. Squibb & Sons, L.L.C.$464
  • Merck$402
  • Philips North America LLC$360
  • AstraZeneca$341
  • plus $2K from 17 others

What the payments were for

  • Travel & lodging$1,75030%
  • Food & beverage$4,05669%
  • Education$371%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,843 in reported general payments places this provider in the 90th percentile of 846 physician assistant providers in Alabama.

See all physician assistant providers in Alabama

Medicare billing

Part B allowed, 2024
$53,195
Medicare patients
437
Services billed
628

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban79$66,855
FarxigaDapagliflozin Propanediol85$64,174
EntrestoSacubitril/Valsartan61$50,241
XareltoRivaroxaban13$12,311
Metoprolol Succinate96$1,417
Flecainide Acetate43$1,399
Ranolazine ErRanolazine15$1,108
Diltiazem 24hr Er (Cd)Diltiazem Hcl31$980
Prasugrel Hcl12$879
Midodrine Hcl16$813
Isosorbide Mononitrate ErIsosorbide Mononitrate43$671
Bumetanide29$645
Potassium Chloride49$644
Atorvastatin Calcium51$566
ClopidogrelClopidogrel Bisulfate44$398

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$77$66,85579 claims
AstraZenecaFarxiga$341$64,17485 claims
NovartisEntresto$213$50,24161 claims
Johnson & JohnsonXarelto$264$12,31113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 846 physician assistant providers in Alabama.

Other physician assistant in Dothan

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →